Deferasirox in thalassemia: a comparative study between an innovator drug and its copy among a sample of Iraqi patients.

Exjade® showed a better ability to reduce SF, with less liver toxicity, and better hemostasis profile. No congenital anomalies associated with short-term use of both drugs during pregnancy were observed or reported.